Frequency of Major Noncardiac Surgery and Subsequent Adverse Events in the Year After Drug-Eluting Stent Placement Results From the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry by Berger, Peter B. et al.
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bjectives This study sought to determine the frequency of noncardiac surgery and adverse post-
perative events among patients who recently received a drug-eluting stent (DES) following noncar-
iac surgery.
ackground Little is known about frequency of and risks associated with noncardiac surgery after
ES implantation.
ethods In the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry, consecutive
atients who underwent attempted stent placement at 42 hospitals between July 2004 and Septem-
er 2005 were enrolled and followed for 1 year. In this study, we analyzed patients who received
1 DES to determine the frequency of noncardiac surgery and cardiac death, myocardial infarction,
r stent thrombosis in the following week.
esults Among 4,637 DES recipients, 206 (4.4%) underwent major noncardiac surgery in the follow-
ng year (median days to surgery: 179 [interquartile range 112 to 266 days; range 13 to 360 days]).
verall, stent use averaged 1.5 per patient. The most frequent operations were orthopedic (36%),
bdominal (31%), and vascular (20%). Compared with patients who did not undergo surgery, those
ho did were older, more likely to be women, and have had a prior stroke; the frequencies of prior
yocardial infarction, prior coronary artery bypass graft, and diabetes were similar, as were left ven-
ricular ejection fraction and indication for percutaneous coronary intervention. In the 7 days after
urgery, 4 patients had a cardiac death, myocardial infarction, or stent thrombosis (1.9% [exact 95%
onﬁdence interval (CI): 0.5% to 4.9%]). The risk of the composite outcome was increased 27-fold in
he week following noncardiac surgery compared with any other week after stent implantation (haz-
rd ratio [HR]: 27.3 [95% CI: 10.0 to 74.2], p  0.001).
onclusions The frequency of major noncardiac surgery in the year after DES placement is 4%.
lthough the overall risk of adverse outcomes was less than previously reported when surgery is
erformed months after DES placement, it is signiﬁcantly increased in the week after major noncar-
iac surgery. (J Am Coll Cardiol Intv 2010;3:920–7) © 2010 by the American College of Cardiology
oundation
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921oronary revascularization before noncardiac surgery is
elieved to decrease the peri- and post-operative risk in
elected patients (1). However, the risk of coronary throm-
osis appears to be increased in patients who undergo a
oncardiac surgical procedure in the weeks and months after
percutaneous coronary intervention (PCI) in which a
are-metal stent is used (2,3). Little is known, however,
bout the frequency with which noncardiac surgery is
equired after a PCI procedure or the risk of ischemic events
mong patients undergoing noncardiac surgery shortly after
lacement of a drug-eluting stent (DES) (4).
Accordingly, we performed this analysis of the EVENT
Evaluation of Drug-Eluting Stents and Ischemic Events)
egistry to determine the frequency with which cardiac
urgery is required in the year after PCI in which a DES is
laced and the risk of adverse cardiac events in the week
ollowing the surgical procedure.
ethods
detailed description of the EVENT registry has been
ublished previously (5). Briefly, the EVENT registry was
aunched shortly after the approval of the first DES in the
.S. to assess the practice of PCI utilizing intracoronary
tents of any kind. Unselected patients undergoing at-
empted stent implantation were enrolled. Four waves of
nrollment of approximately 2,500 patients per wave were
erformed. Forty-two U.S. medical centers (74% academic,
edian PCI volume 1,400/year) participated in the first 2
aves. Clinical and procedural data were prospectively
ollected on standardized case report forms and submitted
o a data coordinating center. Creatine kinase and creatine
inase-myocardial band (CK-MB) levels were assessed at
aseline and every 8 h for a minimum of 2 post-procedure
amples and assayed using each site’s clinical laboratory.
atients were contacted by telephone 6 and 12 months after
he index PCI; only 176 of 2,321 patients (7.6%) were lost
o follow-up in Wave I, and 185 of 2,316 patients (8.0%)
ere lost to follow-up in Wave II. Events noted at
ollow-up for this analysis included cardiac death, myocar-
ial infarction (MI), stent thrombosis, and performance of a
oncardiac surgical procedure. The use of aspirin and
lopidogrel was also assessed at each time point. The
VENT study protocol was approved by the ethical review
ommittee at all participating institutions, and all patients
rovided written informed consent.
ccumetrics, AstraZeneca, Haemoscope, The Medicines Company, Corgenix/
spirinworks, and Eli Lilly/Daiichi-Sankyo and has been a consultant to Accumet-
ics, The Medicines Company, Novartis/Portola, Guerbet, PlaCor, Eli Lilly/Daiichi-
ankyo; and he owns equity in Lumen Inc. (a company that is developing an embolic
rotection device). Dr. Kleiman has received research grants from Sanofi-Aventis,
ordis, Eli Lilly, and Schering-Plough. Dr. Pencina is a consultant with Harvard
linical Research Institute which works with numerous industry clients and serves on
SMB of device/drug trials. Dr. Steinhubl is an employee with stock options of The Mtudy population. In this analysis, consecutive patients en-
olled in the first 2 waves of EVENT who received1 DES
ere analyzed to determine the frequency of noncardiac
urgery in the year after the PCI procedure and the
requency of adverse events in the 7 days after the surgical
rocedure. The 7-day period was determined a priori, in
dvance of this analysis, in view of the fact that essentially all
atients who undergo noncardiac surgery would be expected
o be on dual antiplatelet therapy 1 week after surgery and
hat events occurring 7 days after surgery may not have
een truly related to the surgical procedure. Patients who
eceived a bare-metal stent in addition to a DES (n  186)
ere included in the analysis; patients receiving only a
are-metal stent (n  339, 6.7%), those in whom no stent
ould be implanted (n  48, 0.9%), patients requiring
oronary artery bypass surgery before discharge from the
ndex PCI procedure (n  16, 0.32%), and those who died
uring the index hospitalization (n  1, 0.22%) were not
ncluded in this analysis. Only major noncardiac surgical
rocedures in which a significant surgical incision was
equired from which bleeding would result were included in
his analysis. Patients who underwent coronary artery bypass
urgery or valve surgery (n 
7), pacemaker and defibrillator
lacement (n  46), and pa-
ients who underwent surgery
hose nature could not be deter-
ined (n  50) were prospec-
ively excluded from this analy-
is. Patients who underwent
inor surgical procedures (n 
7), such as minor dermatologi-
al procedures, endoscopic procedures, joint aspirations, and
ataract surgery, were prospectively considered not to have
ndergone major noncardiac surgery and were included in
he control group.
eﬁnitions, adjudication of events, and study outcomes.
he main outcome measure was a composite of cardiac
eath, MI, or definite stent thrombosis in the week after
oncardiac surgery. The definition of MI unrelated to a
evascularization procedure was a clinical syndrome com-
atible with MI associated with a typical rise and fall in
ither CK (with a positive CK-MB or troponin) or CK-MB
o at least twice the upper limit of normal. Stent thrombosis
as independently adjudicated and, for the purposes of this
tudy, considered to have occurred when it met the Aca-
edicines Company. He has received research support from Regado Biosciences,
he Medicines Company, and Eli Lilly/Daiichi Sankyo; and honoraria for serving on
he advisory boards of Sanofi-Aventis/Bristol-Myers Squibb, Eli Lilly/Daiichi
ankyo, Cardax Pharmaceuticals, Portola Pharmaceuticals, and AstraZeneca. Dr.
ohen has received research grant support from Boston Scientific and Abbott
ascular and has received consulting fees from Cordis, Medtronic, Inc., and Eli Lilly.
Abbreviations
and Acronyms
CK-MB  creatine kinase-
myocardial band
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary interventionanuscript received March 10, 2010, accepted March 18, 2010.
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922Table 1. Baseline Characteristics of the Study Population and of Patients Who Did and Did Not Undergo Major Noncardiac Surgery in the Year After
Receiving a DES
Demographic
All Patients
(n  4,637)
No Major Noncardiac Surgery
(n  4,431)
Major Noncardiac Surgery
(n  206) p Value
Age, yrs
Mean  SD, n 64.2 11.5 64.1 11.5 66.9 10.4 0.001
Range (min, max) (21, 95) (21, 95) (40, 91)
Age 80 yrs, % 9.7 9.6 12.6 0.151
Men, % 68.8 69.1 61.2 0.016
Diabetes, % 33.8 33.6 36.4 0.409
Hypertension, % 77.4 77.1 84.0 0.021
Hyperlipidemia, % 73.5 73.5 72.7 0.790
Current smoking, % 24.0 24.4 16.7 0.012
Renal dialysis, % 1.2 1.1 2.9 0.020
CVA, % 8.3 8.1 12.6 0.021
Heart failure, % 10.1 9.8 16.2 0.003
Peripheral arterial disease, % 9.6 9.2 17.2 0.001
MI, % 36.9 36.8 38.6 0.595
PCI, % 36.5 36.5 36.6 0.979
CABG 20.5 20.3 24.8 0.125
Number of diseased vessels
Mean  SD, n 1.7 0.8 1.7 0.8 1.8 0.8 0.380
1, % 47.9 48.1 44.9 0.367
2, % 31.3 31.2 32.7
3, % 20.8 20.7 22.4
MI within 7 days, % 10.5 10.5 9.4 0.616
Indication for PCI (multiple indications allowed), %
Chronic stable angina 20.7 21.0 14.6 0.026
Positive stress test 36.5 36.3 39.3 0.384
Acute coronary syndrome 33.4 33.2 38.3 0.127
STEMI (primary or rescue) 5.2 5.3 3.9 0.371
Post-STEMI 0.7 0.7 1.0 0.651
Heart failure 1.8 1.7 2.4 0.463
Arrhythmia 1.0 1.0 0.5 0.468
Noncardiac surgery 1.1 1.0 3.4 0.001
Other 7.1 7.2 5.3 0.305
Ejection fraction, % 0.751
25 2.6 2.7 1.5
25–35 6.3 6.3 5.8
36–50 20.2 20.1 22.8
50 52.9 52.9 52.4
Unknown 18.0 18.0 17.5
NYHA functional class heart failure, % 0.044
I 38.5 38.2 44.2
II 21.0 21.3 13.6
III 11.0 10.9 12.1
IV 9.9 9.8 12.6
Unknown 19.6 19.7 17.5
CCS class angina, % 0.632
No angina 14.7 14.6 17.5
I 12.9 12.9 11.2
II 24.0 24.1 20.9
III 19.7 19.7 20.4
IV 19.4 19.3 19.9
Creatinine 2.0 mg/dl, % 3.1 2.8 7.7 0.001
CABG coronary artery bypass graft; CCS Canadian Cardiovascular Society; CVA cardiovascular accident; DES drug-eluting stent(s); MImyocardial infarction; NYHA New York Heart Association;PCI percutaneous coronary intervention; STEMI ST-segment elevation myocardial infarction.
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923emic Research Consortium’s definition of definite stent
hrombosis (6).
tatistical methods. Data are presented as means, with
tandard deviations, or medians, with 25th and 75th per-
entiles. Comparisons between the 2 groups were performed
sing a chi-square analysis for discrete variables and Student
test for continuous variables. Cox proportional hazards
egression was performed with the composite of cardiac
eath, MI, or stent thrombosis as primary outcome and the
resence of noncardiac surgery as time-dependent exposure,
ith a focus only on the first 7 days after the noncardiac
urgery. We attempted to confirm the results of the pro-
ortional hazards model using exact methods and obtained
imilar results. In addition to a univariate model described
reviously, we ran the same model but adjusted for covari-
tes measured at the time of stent implantation (and not
pdated during follow-up), which included age, sex, use of
t least 1 Taxus stent (Boston Scientific, Natick, Massachu-
etts), congestive heart failure, creatinine 2.0 mg/dl, left
nterior descending lesion location, bifurcation lesion, total
tent length, number of lesions, and maximum balloon
iameter. Similar analyses were conducted for cardiac death
lone and cardiac death or MI as end points.
esults
aseline and procedural characteristics. Among the 4,637
ES recipients in the first 2 waves of the EVENT study,
06 patients (4.4%) underwent major noncardiac surgery in
he first year after their index PCI. In only 7 of the 4,637
atients (0.15%) was a planned surgical procedure listed as
n indication for the PCI.
The baseline characteristics of patients in the overall
tudy population, and of patients who did and did not
ndergo major noncardiac surgery, are presented in Table 1.
verall, 34% had diabetes mellitus, 37% had had a prior
I, 21% had undergone a prior coronary artery bypass graft,
2% had multivessel disease, 33% had 1 lesion treated
uring the index procedure, and more than 90% of patients
reated received a stent.
Compared with patients who did not undergo surgery,
hose who did were older (age 67 vs. 64 years, p  0.001),
ore likely to be women (39% vs. 31%, p  0.016), and
ave had a prior stroke (13% vs. 8%, p  0.021). The
requencies of prior MI (39% vs. 37%), prior coronary artery
ypass graft (25% vs. 20%), and diabetes (36% vs. 34%) were
imilar, as were left ventricular ejection fraction and the
ndication for PCI.
The timing of surgery, and the angiographic and proce-
ural characteristics of the study population and in patients
ho did or did not undergo surgery, are displayed in Figure
and Table 2. Overall, stent use averaged 1.5 per patient;
3% of patients received a Taxus stent and 51% of patients
eceived a Cypher stent (Cordis Corporation, Bridgewater, gew Jersey); 7% received at least 1 bare-metal stent in
ddition to a DES.
edications. The medications prescribed at discharge after
he index PCI are listed in Table 3. Data about how aspirin
nd clopidogrel were managed in surgical patients were not
ollected in such a way that it could be determined which
atients remained on therapy during the surgery and those
ho did not. However, patients who underwent noncardiac
urgery were less likely to be taking aspirin and clopidogrel
t 1 year (54% vs. 64%, p  0.001).
urgical procedures. The time to surgery is displayed in
igure 1. The median time to surgery was 179 days (112,
66) (range 13 to 360 days). The operations performed were
rthopedic (36%), abdominal (31%), vascular (20%), ear/
ose/throat (4%), thoracic (3%), urologic (1%), intracranial
1%), and other (4%).
ajor adverse events. In the first 7 days after surgery, 4 of
he 206 patients (1.9% [exact 95% confidence interval (CI):
.5% to 4.9%]) suffered a major cardiac event: 1 died and 3
uffered an MI. No patient suffered definite stent
hrombosis.
There was no difference in the timing of surgery among
atients who did and did not suffer a cardiac event (median:
56 vs. 181 days, p  0.40).
To determine whether cardiac risk was increased in the
mmediate peri-operative period, we performed a time-
pdated proportional hazards analysis in which the period of
nterest was the 7 days following noncardiac surgery.
mong patients who did not undergo surgery, the risk of an
vent in any week of follow-up was 0.67% (exact 95% CI:
.56% to 0.078%); the risk per week of cardiac death was
.01%, of MI was 0.14%, and of stent thrombosis was
.002%. In a univariate analysis, the performance of non-
ardiac surgery was associated with a 27-fold increased risk
f ischemic complications during the week following sur-
Figure 1. The Timing of Surgery Among the 206 Patients in EVENT Who
Underwent Major Noncardiac Surgery
Few patients underwent surgery in the ﬁrst 2 months after drug-eluting stent
(DES) implantation; one-half went to surgery 6 or more months after the DES
procedure. EVENT  Evaluation of Drug-Eluting Stents and Ischemic Events.ery compared with any other week after stent implantation
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924Table 2. Angiographic and Procedural Characteristics of the Study Population
All Patients (n  4,637)
All Lesions (n  6,513)
No Major Noncardiac Surgery (n  4,431)
Lesions (n  6,233)
Major Noncardiac Surgery (n  206)
Lesions (n  280) p Value
Target lesion vessel, % 0.014
LAD 35.9 36.3 26.1
Circumﬂex 23.1 22.9 25.7
RCA 33.3 33.0 38.9
LMCA 1.5 1.5 1.4
SVG 6.3 6.3 7.9
Lesion classiﬁcation, % 0.842
A 12.1 12.1 11.5
B1 33.7 33.7 34.8
B2 32.8 32.8 31.2
C 21.4 21.4 22.6
Pre-procedure diameter stenosis, %
Mean  SD, n 84 11 84 11 84 12 0.982
Median 85 85 90
Pre-procedure TIMI ﬂow grade, % 0.915
0 6.5 6.5 5.7
1 4.6 4.5 5.4
2 8.1 8.2 7.9
3 80.8 80.8 81.0
Bifurcation, % 12.1 11.9 16.1 0.036
Thrombus, % 10.0 10.1 7.9 0.220
Post-procedure diameter stenosis
Mean  SD, n 1.61 7.60 1.63 7.69 1.06 5.09 0.077
Lesions per patient
Mean  SD, n 1.4 0.7 1.4 0.7 1.4 0.6 0.306
Range (min, max), % (1, 4) (1, 4) (1, 4)
Median (IQR), % 1 (1–2) 1 (1–2) 1 (1–2)
Number of lesions treated, % 0.412
1 67.6 67.5 69.4
2 25.4 25.4 26.7
3 5.9 6.1 2.4
4 1.1 1.0 1.5
Stents per patient
Mean  SD, n 1.7 0.9 1.7 0.9 1.5 0.8 0.068
Range (min, max), % (1, 7) (1, 7) (1, 6)
Median (IQR), % 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
0, % 0.0 0.0 0.1 0.135
1, % 57 57 60
2, % 28 28 29
3, % 10 10 6.8
4, % 3.5 3.5 2.4
4, % 1.4 1.4 1.0
No. of vessels treated per patient
Mean  SD, n 1.16 0.38 1.16 0.38 1.11 0.33 0.054
1, % 85.2% 85.0% 89.3% 0.086
2, % 14.1% 14.3% 10.2%
3, % 0.7% 0.7% 0.5%Continued on next page
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925mong patients who did not undergo surgery (hazard ratio
HR]: 27.3 [95% CI: 10.0 to 74.2], p  0.001). The
ncreased risk remained similar in multivariable-adjusted
nalyses (25.7 [95% CI: 9.4 to 70.0], p  0.0001). Only
ongestive heart failure, creatinine 2.0 mg/dl, and the
umber of lesions treated were significantly related to the
rimary outcome of interest in addition to our main
xposure (Table 4).
iscussion
he most important findings of this study were that more
han 4% of patients required a major surgical procedure
n the year after placement of a DES. Among such patients,
he risk of cardiac death, MI, or stent thrombosis was 1.9%
exact 95% CI: 0.5% to 4.9%) in the week following surgery,
ower than suggested by previously reported case series
hen surgery was performed earlier, generally in the first
months, after stent placement. However, the risk of a
ajor adverse event in the week after surgery in patients
ho had received a DES within the prior year was
onetheless much higher in a time-dependent propor-
Table 2. Continued
All Patients (n  4,637)
All Lesions (n  6,513)
No Major N
Total stent length
Mean  SD, n 30.7 19.9
Median (IQR), % 24 (16–40)
10 mm, % 3.4
10–19 mm, % 33.2
20–29 mm, % 23.7
30–39 mm, % 14.5
40–59 mm, % 15.9
IQR interquartile range; LAD left anterior descending; LMCA left main coronary artery; RCA
Table 3. Medications at the Time of Discharge After
All Patients
(n  4,637)
No Ma
Aspirin 96.9
Clopidogrel 96.2
Warfarin 5.1
Statin 80.4
Nonstatin lipid-lowering agent 14.3
Beta blocker 76.7
Calcium channel blocker 17.8
ACE inhibitor 48.2
Angiotensin receptor blocker 11.3
Nitrates (other than SL) 16.7
Values are presented as %.ACE angiotensin-converting enzyme; SL sublingual; other abbreviatioional hazards analysis than in patients in whom surgery
as not performed.
ackground. The first small study of patients undergoing
oncardiac surgery after bare-metal stent placement re-
orted a 34% mortality (8 of 25 patients) rate when surgery
as performed in the 2 weeks after surgery; there were no
eaths among the 15 patients who underwent surgery 3 to 8
eeks after bare-metal stent placement (2). A much larger
tudy of 207 patients subsequently identified a 3% to 5%
ate of major adverse events when surgery was performed
nytime during the 6 weeks after stent placement; no
dverse events occurred when surgery was performed be-
ond this time frame (3). These studies, and all such
nalyses, are inherently biased in that patients who required
urgery more rapidly were undoubtedly sicker in 1 or more
ays. It is interesting, however, that a similar analysis of the
isk of noncardiac surgery among 197 patients who under-
ent pre-operative balloon angioplasty did not reveal a high
ate of death or MI when surgery was performed shortly
fter the procedure (although repeat revascularization was
equired more frequently, as is expected when balloon
ngioplasty is compared with stent placement) (7).
diac Surgery (n  4,431)
s (n  6,233)
Major Noncardiac Surgery (n  206)
Lesions (n  280) p Value
0.8 20.0 27.7 17.3 0.012
4 (16–40) 22 (16–34)
3.4 3.4 0.099
33.2 34.0
23.4 31.1
14.6 12.6
16.0 13.1
coronary artery; SVG saphenous vein graft; TIMI Thrombolysis In Myocardial Infarction.
CI Procedure in the Study Population
ncardiac Surgery
4,431)
Major Noncardiac Surgery
(n  206) p Value
96.9 97.0 0.907
96.1 98.9 0.156
5.1 4.5 0.679
80.2 85.1 0.085
14.3 13.4 0.704
76.6 77.7 0.719
17.6 21.3 0.180
48.4 43.6 0.181
11.1 15.8 0.037
16.4 23.3 0.011oncar
Lesion
3
2the P
jor No
(n n as in Table 1.
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926Investigators from the Cleveland Clinic recently reported
he clinical outcome of 606 inpatient surgeries performed
n 481 patients with a mean time from PCI to surgery of
.1  0.9 years (8). Unlike the present study, many patients
ndergoing cardiac surgery were included in that analysis.
eath, MI, or stent thrombosis occurred after 11 (2.0%)
urgeries. The risk decreased significantly in the 1 to 6
onths after PCI, although some risk persisted when the
ime between PCI and surgery was even as long 12 months.
ndependent correlates of the combined end point include
mergency surgery, antecedent MI, the pre-operative use of
ntravenous heparin, and atherosclerotic lesion length
reated with DES. Oral antiplatelet status at time of surgery
as not a correlate of events.
he current study. Guidelines for the management of pa-
ients with coronary disease who require noncardiac surgery
ecommend that revascularization not be performed prior to
major surgical procedure unless there are strong indica-
ions for it, and that if revascularization is required prior to
lanned surgery, a bare-metal stent should be placed or even
alloon angioplasty should be performed rather than place-
ent of a DES (1). If a DES was placed before the need for
surgical procedure was recognized, it has been recom-
ended that at least 1 year be allowed to elapse after the
ES was implanted before surgery is performed and that
ual antiplatelet therapy be continued perioperatively when-
ver the surgery can be safely performed during such therapy
1,9). Although these recommendations are entirely reason-
ble and consistent with the available data, our study is not
ble to directly address these recommendations. The main
onclusions that can be derived from the current study are
hat the need for surgery in the year after PCI is 4%,
mphasizing the importance of patient education prior to
ospital discharge after a PCI procedure about the impor-
ance of consulting with one’s cardiologist regarding the
Table 4. Multivariate Analysis of the Occurrence of Cardiac Death,
MI, or Stent Thrombosis in the 7 Days After Surgery
Variable p Value Hazard Ratio
95% CI for
Hazard Ratio
Noncardiac surgery 0.0001 27.113 9.916–74.136
Age 0.4044 0.994 0.979–1.008
Sex 0.9767 1.005 0.702–1.439
Use of at least 1 Taxus stent 0.1855 0.796 0.569–1.115
CHF 0.0001 2.796 1.871–4.178
Creatinine 2.0 mg/dl 0.0005 2.783 1.568–4.939
LAD lesion 0.3333 0.842 0.595–1.192
Bifurcation lesion 0.6463 0.891 0.544–1.458
Total stent length 0.6770 1.002 0.992–1.012
No. of lesions 0.0843 1.312 0.964–1.784
Maximum balloon diameter 0.0675 0.744 0.541–1.022
CHF congestive heart failure; CI confidence interval; other abbreviations as in Tables 1 and 2.anagement of dual antiplatelet therapy in the periopera- tive period. The other main conclusion is that major
oncardiac surgery appears to be safer than was believed
hen performed months after receipt of a DES and likely is
afer than when surgery is performed within 2 months after
tent placement. Our data do suggest, however, that the risk
f a major adverse event in the week after surgery is
ncreased 27-fold above patients not requiring surgery, even
hough in absolute terms, the risk (1.9% [exact 95% CI:
.5% to 4.9%]) may be lower than previously believed.
In this analysis, when surgery was performed months
fter stent placement, there was no evidence that the
uration between surgery and DES implantation influenced
utcome. However, this relatively small study of 209 pa-
ients cannot determine the optimal duration of delay
etween stent placement and surgery, and the guidelines
hat recommend delaying entirely elective surgery for at
east 1 year would appear to be prudent. Although there
ere no episodes of proven stent thrombosis among patients
fter noncardiac surgery, most patients with perioperative
I did not undergo coronary angiography; the possibility
hat some patients who suffered MI or even death may have
uffered stent thrombosis as well cannot be excluded.
erioperative medical management. Patients who under-
ent noncardiac surgery were significantly less likely to
omplete 1 year of dual antiplatelet therapy. Although we
ere not able to collect detailed data about the management
f dual antiplatelet therapy at the time of each surgical
pisode, the finding that patients who underwent surgery
ere less likely to be taking clopidogrel 1 year after DES
lacement suggests that at least some patients probably had
heir clopidogrel discontinued at the time of surgery and
hat it was not restarted. Continued patient and physician
ducation regarding the importance of restarting aspirin and
lopidogrel (if these medications indeed must be discontin-
ed pre-operatively) is required to prevent catastrophic
vents in this challenging patient cohort.
tudy limitations. There are several important limitations to
his analysis that physicians ought to keep in mind when
eciding whether or to what extent this analysis ought to
nfluence their practice patterns. The way in which the
spirin and clopidogrel were managed in these patients
ould not be gleaned from the EVENT registry data
ollection forms. Because aspirin and clopidogrel reduce the
requency of stent thrombosis, it is likely that the adverse
vent rate might be influenced by whether these medica-
ions were administered perioperatively; the event rate is
xpected to be higher if patients had not been continued on
ual antiplatelet therapy perioperatively, and lower, possi-
ly, if all had been continued on aspirin and clopidogrel.
ardiologists were likely aware, at the time of this study, of
he reports of stent thrombosis after surgery in patients with
ecently placed DES. There may well have been selection
ias toward the “healthiest” of patients who were “permit-
ed” to undergo noncardiac surgery, and physicians may
h
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927ave been more aggressive about using aspirin and clopi-
ogrel in such patients than described in previous reports.
efinitions of stent thrombosis are all imperfect. It is likely
hat some cases of stent thrombosis were not recognized
linically; therefore, it is possible that the current data
epresent an under-reporting of the true frequency of stent
hrombosis. Also, the risk of perioperative thrombotic
vents only partially captures the potential risk of DES-
reated patients undergoing surgery. No data were captured
o allow for a description of bleeding events in the post-
perative period. The risk of performing surgery in patients
ith coronary disease is known to be higher than in patients
ithout coronary disease; whether the rate of major adverse
vents is related to the recent implantation of a DES cannot
e determined from this study. Randomized trials have
ndicated that such events are not prevented by the routine
erformance of revascularization in patients with stable
oronary disease; some data suggest it may be increased.
astly, few adverse events occurred in the study population,
articularly among those who underwent surgery. The
ncertainty of estimates of risk is reflected in the wide
onfidence intervals.
onclusions
n the modern stent era, the frequency of major noncardiac
urgery in the year after DES placement is nearly 5%,
ccurring in approximately 0.5% of patients per month after
he first 2 months. Although the overall risk of adverse
utcomes appears to be less than previously reported, it is
ignificantly increased in the week after major noncardiac
urgery. Improved patient and physician education is war-
anted to delay truly elective noncardiac surgery and to
mprove rates of compliance with recommendations for
spirin and clopidogrel therapy during or after the periop-
rative period when possible. deprint requests and correspondence: Dr. Peter B. Berger,
eisinger Center for Clinical Studies, 100 North Academy Ave-
ue, MC 40-00, Danville, Pennsylvania 17822-4400. E-mail:
bberger@geisinger.edu.
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